Germany-based Medigene AG continued to progress its pipeline of cellular immunotherapies for cancer in the first half year of 2020 with the launch of a Phase 1 trial of a candidate product for patients suffering from relapsed blood cancers.
Germany-based CureVac BV, which is developing a messenger RNA (mRNA) vaccine against Covid-19, has made an initial public offering of its shares on the US Nasdaq market raising approximately $213.3 million. The offering is expected to close on 18 August.
It consists of 13.3 million common shares at a price of £16 per share Underwriters have a 30-day option to purchase up to an additional 1.9 million shares at the offer price, less underwriting discounts and commissions. The shares were scheduled to start trading on 14 August.
H. Lundbeck A/S generated a 5% increase in revenue to DKK 8.9 billion (€1.2 billion) in the first half of 2020, while also recording higher spending on research and development. This included spending on a newly approved product for migraine as well as the impairment of an asset.